Cardiff Oncology Inc (CRDF) Stock: Navigating the Market Volatility

The stock of Cardiff Oncology Inc (CRDF) has seen a 8.02% increase in the past week, with a 70.17% gain in the past month, and a 305.96% flourish in the past quarter. The volatility ratio for the week is 9.30%, and the volatility levels for the past 30 days are at 15.98% for CRDF. The simple moving average for the last 20 days is 23.36% for CRDF stock, with a simple moving average of 230.45% for the last 200 days.

Is It Worth Investing in Cardiff Oncology Inc (NASDAQ: CRDF) Right Now?

Company’s 36-month beta value is 1.97.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for CRDF is 41.07M, and currently, short sellers hold a 6.85% ratio of that floaft. The average trading volume of CRDF on April 04, 2024 was 1.67M shares.

CRDF) stock’s latest price update

The stock of Cardiff Oncology Inc (NASDAQ: CRDF) has increased by 16.53 when compared to last closing price of 5.33. Despite this, the company has experienced a 8.02% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-01 that Cardiff Oncology (CRDF) made it through our “Recent Price Strength” screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Analysts’ Opinion of CRDF

Robert W. Baird, on the other hand, stated in their research note that they expect to see CRDF reach a price target of $19. The rating they have provided for CRDF stocks is “Outperform” according to the report published on December 08th, 2021.

Maxim Group gave a rating of “Buy” to CRDF, setting the target price at $20 in the report published on August 09th of the previous year.

CRDF Trading at 99.13% from the 50-Day Moving Average

After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.25% of loss for the given period.

Volatility was left at 15.98%, however, over the last 30 days, the volatility rate increased by 9.30%, as shares surge +59.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +305.23% upper at present.

During the last 5 trading sessions, CRDF rose by +7.83%, which changed the moving average for the period of 200-days by +294.90% in comparison to the 20-day moving average, which settled at $5.15. In addition, Cardiff Oncology Inc saw 319.68% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRDF starting from PACE GARY W, who purchase 30,000 shares at the price of $1.37 back on Dec 19 ’23. After this action, PACE GARY W now owns 697,761 shares of Cardiff Oncology Inc, valued at $41,100 using the latest closing price.

Stock Fundamentals for CRDF

Current profitability levels for the company are sitting at:

  • -93.06 for the present operating margin
  • 0.18 for the gross margin

The net margin for Cardiff Oncology Inc stands at -83.22. The total capital return value is set at -0.64. Equity return is now at value -47.07, with -41.90 for asset returns.

Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -14.37.

Currently, EBITDA for the company is -45.01 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 532.03. The receivables turnover for the company is 1.69for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.

Conclusion

In a nutshell, Cardiff Oncology Inc (CRDF) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts